ArticleCancer chemotherapy and pharmacology2021
Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis.
Article in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.American journal of translational research · 2025Article
- Development and validation of an individualized nomogram for gastric cancer patients treated with perioperative chemotherapy followed by radical surgery.Translational gastroenterology and hepatology · 2024Article
- Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.International immunopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSome cancer patients experience an increase in the leukocyte count, platelet count, and absolute neutrophil count compared to the baseline level after chemotherapy. We identify this phenomenon as "myelostimulation", which seems to go against the myelosuppression properties of chemotherapy drugs. However, the clinical value of "myelostimulation" that appears early after fluorouracil plus platinum-based neoadjuvant chemotherapy (NACT) in patients with locally advanced gastric cancer (LAGC) remains unclear.
methodPatients with LAGC who underwent fluorouracil plus platinum-based NACT and radical resection from January 2010 to January 2015 were included. Patients were divided into an increased group and a decreased group based on the leukocyte count, platelet count, and absolute neutrophil count in the early stage after NACT, compared with the baseline blood routine examination results. The prognosis was compared between the increased group and the decreased group.
resultsThe 3-year PFS and 5-year OS of the group with increased leukocyte count, platelet count, and absolute neutrophil count were significantly lower compared to those of the decreased group. Based on the multivariate analysis, increased absolute neutrophil count is an independent risk factor for 3-year PFS (P < 0.001, HR 3.003, 95% CI 1.639-5.495) and 5-year OS (P = 0.003, HR 2.611, 95% CI 1.374-4.950), and increased platelet count is an independent risk factor for 5-year OS (P = 0.037, HR 2.033, 95% CI 1.044-3.953).
conclusionThe "myelostimulation" that occurs in patients with LAGC in the early stage (3-5 days) after fluorouracil plus platinum-based NACT is related to a poor prognosis, which is a simple and effective method to screen related patients with unfavored outcomes. Notably, the increase in absolute neutrophil count and platelet count has been proved to be an independent risk factor.
Indexed as
Identifiers
33611625What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.